MedPath

Quality of Life in Patients Undergoing Embolization Using Yttrium Y 90 Glass Microspheres for Primary or Metastatic Liver Cancer

Completed
Conditions
Liver Cancer
Metastatic Cancer
Registration Number
NCT00739167
Lead Sponsor
Northwestern University
Brief Summary

RATIONALE: Learning about quality of life in patients with cancer undergoing embolization may help doctors learn about the side effects of treatment and plan the best treatment.

PURPOSE: This clinical trial is studying quality of life in patients undergoing embolization using yttrium Y 90 glass microspheres for primary or metastatic liver cancer.

Detailed Description

OBJECTIVES:

Primary

* Assess the quality of life (QOL) as defined by the presence or absence of physical, social, emotional, and functional distress in patients with primary or metastatic liver cancer undergoing treatment with radioembolization or transcatheter arterial embolization.

* Compare the time course of QOL measures between treatment groups in patients treated with these regimens.

* Compare the time course of QOL measures between patient subgroups defined by pre-treatment quality of life or tumor burden.

OUTLINE: Patients complete FACT-Hep version 4 surveys on quality of life prior to initiation of embolization, and at 2 weeks and 1 month after completion of embolization.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
74
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Quality of life differences between treatment groupsBefore treatment, 2 weeks post, and 1 month post
Quality of life of all patients over the course of treatmentBefore treatment, 2 weeks post, and 1 month post
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Robert H. Lurie Comprehensive Cancer Center at Northwestern University

🇺🇸

Chicago, Illinois, United States

© Copyright 2025. All Rights Reserved by MedPath